Article
Pharmacokinetics and Drug-Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping.
Clinical pharmacology and therapeutics - 1 Apr 2021
Gausi Kamunkhwala, Wiesner Lubbe, Norman Jennifer, Wallis Carole L, Onyango-Makumbi Carolyne, Chipato Tsungai, Haas David W, Browning Renee, Chakhtoura Nahida, Montepiedra Grace, Aaron Lisa, McCarthy Katie, Bradford Sarah, Vhembo Tichaona, Stranix-Chibanda Lynda, Masheto Gaerolwe R, Violari Avy, Mmbaga Blandina T, Aurpibul Linda, Bhosale Ramesh, Nevrekhar Neetal, Rouzier Vanessa, Kabugho Enid, Mutambanengwe Mercy, Chanaiwa Vongai, Nyati Mandisa, Mhembere Tsungai, Tongprasert Fuanglada, Hesseling Anneke, Shin Katherine, Zimmer Bonnie, Costello Diane, Jean-Philippe Patrick, Sterling Timothy R, Theron Gerhard, Weinberg Adriana, Gupta Amita, Denti Paolo
Abstract excerpt
The World Health Organization guidelines recommend that individuals living with HIV receive ≥ 6 months of isoniazid preventive therapy, including pregnant women. Yet, plasma isoniazid exposure during pregnancy, in the antiretroviral therapy era, has not been well-described. We investigated pregnancy-induced and pharmacogenetic-associated pharmacokinetic changes and drug-drug interactions between isoniazid and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
